WB-308 is a small-molecule EGFR inhibitor that suppresses proliferation and clonogenicity of non-small cell lung cancer (NSCLC) cells, induces G2/M cell cycle arrest and apoptosis, and inhibits tumor growth in both orthotopic lung xenograft and patient-derived xenograft mouse models; it also reduces phosphorylation of EGFR, AKT, and ERK1/2 proteins; due to its lower cytotoxicity compared to Gefitinib, WB-308 is a novel EGFR tyrosine kinase inhibitor (EGFR-TKI) with potential as an alternative to Gefitinib for NSCLC therapy.